Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy treatment. The patient was a young man who suffered acute liver failure after being treated with Elevidys, according to a March 18 company news…

Mark Cuban Cost Plus Drug Co. is disrupting the traditional hospital pharmaceutical purchasing model, according to leaders at ScionHealth, which partnered with Cost Plus Drugs nearly a year ago.  In May, Louisville, Ky.-based ScionHealth became the second health system to…

Biotech company Valo Health and AI healthcare firm nference have entered into a multi-year partnership to leverage AI and patient data in drug discovery and development.  The collaboration will integrate nference’s AI platform, which processes de-identified data from top academic…

A new Academy of Managed Care Pharmacy Foundation report, "Emerging Trends Impacting Managed Care Pharmacy," developed in partnership with Pfizer, warned of significant shifts within managed care pharmacies fueled by AI adoption, drug shortages and affordability challenges. 

CMS will not change the Biden administration's plan to negotiate prices for 15 previously named prescription drugs, and the agency's next potential leader says he will defend the program in court.

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress and reported March 13 by…

A recently approved drug for acute ischemic stroke works as well as the treatment used in most U.S. hospitals and may offer advantages for some patients, according to a study led by a researcher from Dallas-based UT Southwestern Medical Center. 

As retail pharmacies continue to shutter across Northeast Ohio, Cleveland-based MetroHealth is working to fill the gaps. 

Four of the 10 medications Statista anticipates will yield the largest sales in 2026 are GLP-1 medications, according to data shared with Becker's. 

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection.